FN2 Earnings Intelligence
DaVita Inc. earnings overview
Latest DaVita Inc. (DVA) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
DaVita Inc.
DaVita’s Q3 results support a constructive operating thesis: clinical progress from expanded HD, mortality-driven census growth, and stronger-than-expected Integrated Kidney Care are potential earnings supports. The evidence is balanced by a narrowed full-year outlook, cost pressure, commercial-mix headwinds, and reimbursement uncertainty.
DaVita Inc.
The supplied Q2 analysis supports a constructive operating picture on treatment demand and execution: volume growth accelerated while management reaffirmed FY2026 targets. That progress is tempered by revenue-per-treatment pressure, reimbursement uncertainty, and the cyber-related headwind.
DaVita Inc.
DaVita's Q1 2026 results exceeded consensus on both lines, with adjusted EPS of $2.87 versus a $2.41 estimate (a 19% surprise) and revenue of $3.42 billion versus $3.36 billion expected. The beat was driven by treatment volume running slightly ahead of forecast, helped by improving mortality trends and patient transfers from Fresenius clinic closures. Management raised full-year guidance for both adjusted operating income (to $2.15-$2.25 billion from $2.085-$2.235 billion) and EPS (to $14.10-$15.20 from $13.60-$15.00), reflecting confidence in sustained volume recovery and operational efficiency from AI and technology investments. The stock surged 23.5% on the report, well ahead of the benchmark's 1.4% move. The quarter marks a shift from the prior quarter's maintained guidance and flat volume narrative toward a more constructive trajectory, though management flagged ACA enrollment…
DaVita Inc.
The latest analysis supports a more constructive view of DaVita’s growth trajectory: IKC profitability, home-health expansion, clinical initiatives, and cost discipline provide potential support, but volume, policy, mortality, and execution risks remain material.
DaVita Inc.
The supplied analysis supports a mixed picture: DaVita’s reaffirmed guidance and technology, AI, and clinical-research initiatives provide support, but declining treatment volume, an IKC operating loss, and policy and payer-mix uncertainty limit confidence in a straightforward growth case.
DaVita Inc.
DaVita’s earnings resilience is supported by cost control and clinical initiatives, but the evidence is mixed because treatment-volume pressure and cyber-related effects remain material.
DaVita Inc.
DaVita's near-term operating narrative remained resilient: reimbursement and international performance supported results while management held guidance through temporary volume and cybersecurity pressures. The evidence is constructive but incomplete because the supplied scorecard does not include actual EPS or revenue.
DaVita Inc.
DaVita's growth case rests on reimbursement changes, home dialysis, Integrated Kidney Care, and Latin American expansion, but the evidence is balanced by modest volume growth, supply constraints, and uncertainty around the size and timing of those benefits.
DaVita Inc.
DaVita's operating trajectory remained supported by efficiency initiatives, integrated kidney care improvements, potential CMS-related reimbursement benefits, and international expansion. The case was balanced by supply disruption, mortality-related volume pressure, regulatory execution, and higher interest expense; management maintained full-year guidance rather than raising it.
Get the DVA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.